<DOC>
	<DOCNO>NCT00690300</DOCNO>
	<brief_summary>The purpose study test combination-therapy oxaliplatin docetaxel patient metastatic locally advanced adenocarcinoma pancreas failure palliative first line therapy .</brief_summary>
	<brief_title>Docetaxel Plus Oxaliplatin Therapy Patients With Pancreatic Cancer</brief_title>
	<detailed_description>For year Fluorouracil establish treatment pancreatic cancer median survival time 8 month . Since 1997 Gemcitabine also standard therapy comparison Fluorouracil significant well clinical benefit . But progression disease palliative first-line therapy establish second line therapy pancreatic cancer . So purpose study test combination Oxaliplatin Docetaxel patient metastatic locally advanced adenocarcinoma pancreas failure palliative first line therapy get reasonable second line concept .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Dated sign informed concent Histologically cytologically proven metastatic locally advanced adenocarcinoma exocrine pancreas ( stadium UICC III/IV ) Presence least one measurable ( accord RECIST criterion ) marker lesion ( primary tumor metastasis ) outside area previously subject radiation therapy Failure palliative first line therapy metastatic locally advanced adenocarcinoma exocrine pancreas due : Progress within 3 month firstline therapy Discontinuation firstline therapy due toxicity Age &gt; = 18 year Karnofsky index &gt; 60 % Expected live span &gt; 12 week Sufficient bone marrow reserve : Granulocytes &gt; = 1.5 x 109/L Platelets &gt; = 100 x 109/L Hemoglobin &gt; = 9 g/L Serum Bilirubin &lt; 2 x upper normal limit 2.5 x upper normal limit case hepatic metastasis ( biliary drainage allow ) AST/ALT &lt; 2.5 x upper normal limit Every cancer secondary cancer besides basal cell carcinoma skin carcinoma situ cervix uterus . Inclusion patient type cancer successfully treat relapse within last 5 year possible Pregnancy lactation Patients able reproduce adhere strict contraception Presence brain metastasis Severe , uncontrolled infection Preexisting peripheral neuropathy &gt; grade I Preexisting severe illness unstable coronary artery disease uncontrolled cardiac arrhythmia Justified disbelief compliance patient Parallel participation another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>pancreatic cancer</keyword>
	<keyword>pancreas carcinoma</keyword>
	<keyword>advanced pancreatic cancer</keyword>
	<keyword>metastatic pancreatic cancer</keyword>
	<keyword>second line</keyword>
	<keyword>palliative</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Taxotere</keyword>
	<keyword>Eloxatin</keyword>
	<keyword>Cancer pancreas</keyword>
	<keyword>Pancreas cancer</keyword>
</DOC>